evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer

Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).

1 finding from 1 review